Advertisement

Effect of norethisterone acetate on serum lipid and lipoprotein parameters as well as on blood coagulation in female monkeys (M. fascicularis)

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The effects of daily oral administration of a high dose of 10 mg norethisterone acetate (NET-Ac.)/kg/day over 14 weeks on serum lipid and lipoprotein parameters as well as on blood coagulation were investigated in female monkeys (M. fascicularis). Measurements of lipids and lipoprotein cholesterol were performed in weeks —5 and — 1 before treatment and in weeks 4, 8 and 12 after treatment. In addition, various blood coagulation and fibrinolytic parameters were determined in weeks 11–14 after treatment with NET-Ac. Furthermore, the serum levels of norethisterone (NET) were determined in order to monitor the real systemic compound exposure and revealed that Cmax and AUC (0–3 h) values reached for norethisterone in this experiment in monkeys were about 25 times higher than those obtained after an oral contraceptive dose of NET-Ac. in women.
      The results of lipid and lipoprotein cholesterol determinations showed decreases in serum total lipids, phospholipids, triglycerides and total cholesterol associated with similar decreases in HDL-, LDL- and VLDL-cholesterol fractions after NET-Ac.-treatment in monkeys. These effects were observed from week 4 onwards and maintained their magnitude up to week 12 after treatment. Since both HDL- and LDL-cholesterol fractions decreased, the HDL/LDL-ratio remained almost unchanged. Thus, the results obtained in this study after high-dose treatment with NET-Ac. in monkeys did not indicate any changes of lipid and lipoprotein parameters which in humans are supposed to be associated with an increased risk of cardiovascular lesions, namely a decrease in HDL- and increase in LDL-cholesterol fractions.
      The results of blood coagulation and fibrinolytic parameters showed increased antithrombin-III and plasminogen levels besides minor changes in other parameters, thus indicating that NET-Ac. -treatment does not contribute to an increased risk of cardiovascular thrombotic events in the cynomolgus monkey.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stadel BV
        Oral contraceptives and cardiovascular disease.
        N Engl J Med. 1981; 305: 612-618
        • Thorogood M
        • Vessey MP
        An epidemiologic survey of cardiovascular disease in women taking oral contraceptives.
        Am J Obstet Gynecol. 1990; 163: 274-281
        • Goldzieher JW
        Orale Kontrazeptiva, Kardiovaskulares Risiko.
        in: Beller FK Giesing M Graeff H Hormonale Kontrazeption und Herzkreislauf. SMV Verlag, Gräfelfing1987: 120-138
        • Stampfer MJ
        • Willett WC
        • Colditz GA
        • Speizer FE
        • Hennekens CH
        A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases.
        N Engl J Med. 1988; 319: 1313-1317
        • Stampfer MJ
        • Willett WC
        • Colditz GA
        • Speizer FE
        • Hennekens CH
        Past use of oral contraceptives and cardiovascular disease: A meta-analysis in the context of the Nurses' Health Study.
        Am J Obstet Gynecol. 1990; 163: 285-291
        • Hennekens CH
        • Evans D
        • Peto R
        Oral contraceptives, cigarette smoking and myocardial infaction.
        Br J Fam Plan. 1979; 5: 66-67
        • Thorogood M
        The epidemiology of cardiovascular disease in relation to the estrogen dose of oral contraceptives: an historical perspective.
        Adv Contraception. 1991; 7: 11-21
        • Harlap S
        Shortcomings in data needed for risk-benefit estimates involving oral contraceptives and cardiovascular disease.
        Adv Contraception. 1991; 7: 54-64
        • Buckmann MT
        • Johnson J
        • Ellis H
        • Srivastava L
        • Peake GT
        Differential lipemic and proteinemic response to oral ethinyl estradiol and parenteral estradiol cypionate.
        Metabolism. 1980; 29: 803-805
        • Basdevant A
        • De Lignieres B
        • Guy-Grand B
        Differential lipemic and hormonal responses to oral and parenteral 17β-estradiol in postmenopausal women.
        Am J Obstet Gynecol. 1983; 147: 77-81
        • Wahl P
        • Walden C
        • Knopp R
        • et al.
        Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
        N Engl J Med. 1983; 308: 862-867
        • Teichmann AT
        • Wieland H
        • Brockerhoff P
        Sexualhormone, Arteriosklerose und Fettstoffwechsel der Frau.
        in: Wiss. Verl.-Ges, Stuttgart1989: 101-115
        • Castelli WP
        The role of plasma lipids as predictors of risk for coronary heart disease.
        Drugs. 1990; 40: 1-6
        • Frick MH
        • Manninen V
        • Huttunen JK
        • Heinonen OP
        • Tenkanen L
        • Manttari M
        HDL-cholesterol as a risk factor in coronary heart disease.
        Drugs. 1990; 40: 7-12
        • Silfverstolpe G
        • Gustafson A
        • Samsioe G
        • Svanborg A
        Lipid metabolic studies in oophorectomised women: effects on serum lipids and lipoproteins of three synthetic progestogens.
        Maturitas. 1982; 4: 103-111
        • Koritnik D
        • Clarkson T
        • Adams M
        Cynomolgus macaques as models for evaluating effects of contraceptive steroids on plasma lipoproteins and coronary atherosclerosis.
        in: Bley R Gregoire A Contraceptive steroids: pharmacology and safety. Plenum Press, New York1986: 303-319
        • Adams MR
        • Rudel LL
        • Clarkson TB
        • Nelson CA
        • Thau RB
        • Moo-Young AJ
        Influence of a levonorgestrel-containing contraceptive vaginal ring on plasma lipids and lipoproteins in cynomolgus monkeys.
        Contraception. 1983; 28: 253-266
        • Hammond GL
        • Lähteenmäki PL
        • Lähteenmäki P
        • Luukkainen T
        Distribution and percentages of non-protein bound contraceptive steroids in human serum.
        J Steroid Biochem. 1982; 17: 375-380
        • Redgrave TG
        • Roberts D.C.K.
        • West CE
        Separation of plasma lipoproteins by density-gradient ultracentrifugation.
        Anal Biochem. 1975; 65: 42-49
        • März W
        • Scharnagel WH
        • Siekmeier R
        • Träger L
        • Gross W
        Fast protein liquid chromatography (FPLC) of plasma lipoproteins.
        J Clin Chem Clin Biochem. 1989; 27: 719
        • Richterich R
        Plasma Fibrinogen: Biuret-Methode.
        in: Klinische Chemie. S. Karger, Basel1971: 315-317
        • Keck G
        • Lam A
        Methodik der Thrombelastography beim Hund.
        Kleintier-Praxis. 1972; 17: 1-9
        • Manchini G
        • Carbonara AO
        • Heremons JF
        Immunochemical quantitation of antigens by single radial immunodiffusion.
        Immunochemistry. 1965; 2: 235-254
        • Saperstein S
        • Edgren RA
        • Jung D
        • et al.
        Pharmacokinetics of norethindrone: effect of particle size.
        Contraception. 1989; 40: 731-740
        • Anderson DC
        Sex-hormone-binding globulin.
        Clin Endocrinol. 1974; 3: 69-96
        • Crona N
        • Silfverstolpe G
        • Samsioe G
        Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
        Contraception. 1984; 29: 261-269
        • Adams MR
        • Clarkson TB
        • Shively CA
        • Parks JS
        • Kaplan JR
        Oral contraceptives, lipoproteins and atherosclerosis.
        Am J Obstet Gynecol. 1990; 163: 1388-1393
        • Shively CA
        • Kaplan JR
        • Clarkson TB
        Carotid artery atherosclerosis in cholesterol-fed female cynomolgus monkeys.
        Arteriosclerosis. 1990; 10: 358-366
        • Clarkson TB
        • Adams M
        • Kaplan JR
        • Shively CA
        • Koritnik DR
        From menarche to menopause: Coronary artery atherosclerosis and protection in cynomolgus monkeys.
        Am J Obstet Gynecol. 1989; 160: 1280-1285
        • Parks JS
        • Pelkey SJ
        • Babiak J
        • Clarkson TB
        Contraceptive steroids effects on lipids and lipoproteins in cynomolgus monkeys.
        Arteriosclerosis. 1989; 9: 261-268
        • Adams MR
        • Clarkson TB
        • Koritnik DR
        • Nash HA
        Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques.
        Fertil Steril. 1987; 47: 1010-1018
        • Teichmann AT
        • Wander HE
        • Cremer P
        • et al.
        Medroxyprogesterone acetate and lipid metabolic changes.
        Arzneim-Forsch/Drug Res. 1987; 37: 573-577
        • Sabra A
        • Bonner J
        Hemostatic system changes induced by 50 μg and 30 μg estrogen/progestogen oral contraceptives.
        J Reprod Med. 1983; 28: 85-91
        • Howie PW
        • Mallinson AC
        • Prentice C.R.M.
        • Horne C.H.W.
        • Menicol GP
        Effect of combined oestrogen-progestogen oral contraceptives, oestrogen and progestogen on antiplasmin and antithrombin activity.
        in: Lancet. 1970: 1329-1332
        • Fotherby K
        The progestogen-only pill thrombosis.
        Br J Fam Plan. 1989; 15: 83-85
        • Ball MJ
        • Ashwell E
        • Gillmer M.D.G.
        Progestogen-only oral-contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone.
        Contraception. 1991; 44: 223-233
        • Singh K
        • Viegas O.A.C.
        • Koh S.C.L.
        • Ratnam SS
        Effect of long-term use of Norplant® implants on haemostatic function.
        Contraception. 1992; 45: 203-219
        • Fahmy K
        • Khairay M
        • Allam G
        • Gobran F
        • Alloush M
        Effect of depo-medroxy-progesterone acetate on coagulation factors and serum lipids in Egyptian women.
        Contraception. 1991; 44: 431-444